PierianDx Announces the Appointment of Mark McDonough as New CEO

ST. LOUIS, MO – November 17, 2020 – PierianDx, the leading clinical genomics
informatics company, today announced the appointment of Mark McDonough as Chief
Executive Officer (CEO) and member of the Board of Directors of PierianDx, effective
immediately. In his new role, McDonough will help fulfill the company’s unique value
proposition of enabling precision medicine through its best-in-class variant interpretation
knowledgebase, integrated infrastructure, and clinical genomics reporting for both
cancer and inherited disease. McDonough succeeds Chairman of the Board and Interim
CEO, Joe Boorady, who remains as Chairman of the PierianDx Board of Directors.

Mark McDonough is a global technology business executive with nearly 30 years of
experience. His personal mission is to impact change in the field of healthcare in a
compassionate yet resolute manner, leading by example. He most recently served as
CEO and board member for Immunis.AI, where he secured funding and developed a
top-flight team within six months to launch a novel noninvasive liquid biopsy
immunogenomics assay for prostate cancer patients on ‘active surveillance’. Prior to
this, McDonough served as President, CEO, and board member of CombiMatrix from
2012 through 2018, orchestrating its sale to Invitae in November 2017. Under his
leadership, CombiMatrix experienced 14 consecutive quarters of record growth. Earlier
in his career, he served in various sales leadership roles within the clinical laboratory
industry and developed his leadership skills as a Navigator and Communications Officer
in the US Navy.

“Mark commands a deep understanding of the diagnostics market, and we are delighted
to welcome him to the PierianDx family during this exciting time in the company’s
development,” says Rakesh Nagarajan, MD, Ph.D., Founder and Chief Visionary and
Technical Officer of PierianDx. “Mark will drive company execution on its IVD strategy
and solidify its leadership position in global cancer and hereditary disease
diagnostics market.”

“I am excited to join PierianDx and lead this talented team committed to delivering tools
to our partners and customers that enable precision medicine adoption at scale,” said
Mark McDonough. “We believe advanced genomic testing should be democratized and
available to all at the highest quality and lowest cost. I look forward to helping propel the
company as we expand our market leadership and serve more patients through our
partners and customers.”

About PierianDx

Founded in 2014 out of Washington University in St. Louis, PierianDx is focused on
advancing cancer diagnostics and making targeted therapeutics more accessible to
healthcare systems, laboratories, and patients worldwide. Its industry-leading clinical
genomics technologies, CAP and CLIA accredited laboratory, IVD-ready
knowledgebase and reporting solution, and expertise deliver the most integrated,
trusted, and collaborative approach across the clinical care spectrum. From genomic
sequencing and biomedical informatics in the laboratory to reporting and decision
support at the patient’s bedside, PierianDx drives the adoption of genomics in clinical
care and accelerates the fight against somatic cancer and hereditary germline diseases.

For more information visit www.pieriandx.com